tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Vaxcyte Signs 15-Year Agreement with Patheon
PremiumCompany AnnouncementsVaxcyte Signs 15-Year Agreement with Patheon
1M ago
Vaxcyte to establish fill-finish manufacturing in North Carolina
Premium
The Fly
Vaxcyte to establish fill-finish manufacturing in North Carolina
1M ago
Vaxcyte initiated with a Neutral at Goldman Sachs
Premium
The Fly
Vaxcyte initiated with a Neutral at Goldman Sachs
2M ago
Vaxcyte’s Strategic Adjustments and Optimized Trials Drive Buy Rating
PremiumRatingsVaxcyte’s Strategic Adjustments and Optimized Trials Drive Buy Rating
3M ago
Promising Prospects for Vaxcyte’s VAX-31: Strong Adult Trial Results and Strategic Advancements in Infant Studies Reinforce Buy Rating
Premium
Ratings
Promising Prospects for Vaxcyte’s VAX-31: Strong Adult Trial Results and Strategic Advancements in Infant Studies Reinforce Buy Rating
3M ago
Vaxcyte reports Q2 EPS ($1.22), consensus ($1.16)
Premium
The Fly
Vaxcyte reports Q2 EPS ($1.22), consensus ($1.16)
3M ago
Vaxcyte’s Long-Term Potential Overshadows Market Challenges: A Buy Recommendation
PremiumRatingsVaxcyte’s Long-Term Potential Overshadows Market Challenges: A Buy Recommendation
6M ago
Optimistic Outlook for Vaxcyte’s Vaccines Drives Buy Rating
Premium
Ratings
Optimistic Outlook for Vaxcyte’s Vaccines Drives Buy Rating
6M ago
Vaxcyte reports Q1 EPS ($1.04), consensus (98c)
Premium
The Fly
Vaxcyte reports Q1 EPS ($1.04), consensus (98c)
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100